By preventing IgE from interacting with high-affinity Fcε receptors on effector cells such as mast cells, omalizumab modulates downstream pro-inflammatory signaling that leads to airway inflammation and may also potentially reduce coagulation abnormalities associated with disease activity (Kaplan et al., 2017). The gene discussed is IGHE; the disease is inflammatory response.